Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regional Absorption of KUC-7483 CL in Healthy Males
NCT02259920Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2003
- Primary completion
- May 2004
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of ritobegron in overactive bladder (OAB) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Area under the concentration-time curve from 0 to infinity up to 24 hours. Started Dec 2003; status: completed.
02
Drugs
ritobegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02259920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259920.